Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy - Seite 2

As Psycheceutical makes progress on its organizational strategy, it is also making strides in advancing its drug development strategy. The company recently announced the successful dosing of the first patient in the historic Phase I clinical trial for its NeuroDirect ketamine topical as a treatment for individuals suffering from PTSD. Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder. As they look forward to the results of that study, the company will continue expanding its clinical trial program to other psychedelic medicines and treatment options for mental health and neurodegenerative disorders. See Psycheceutical's drug pipeline here.

About Psycheceutical Bioscience, Inc.

Psycheceutical Bioscience, Inc. (OTC PINK: BWVI) is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and top neuroscientists, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.

Forward-Looking Statements:

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.